Indivior (NASDAQ:INDV) Rating Lowered to Buy at Wall Street Zen

by · The Markets Daily

Indivior (NASDAQ:INDV – Get Free Report) was downgraded by investment analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

Several other research firms have also recently weighed in on INDV. Weiss Ratings cut Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, September 24th. Craig Hallum reiterated a “buy” rating and set a $53.00 target price on shares of Indivior in a research report on Tuesday, August 4th. Barclays lifted their price target on shares of Indivior from $43.00 to $45.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 28th. Finally, Zacks Research raised Indivior from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 2nd. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $46.40.

Get Our Latest Report on Indivior

Indivior Price Performance

NASDAQ:INDV opened at $35.37 on Friday. The company has a market cap of $4.18 billion, a PE ratio of 9.88 and a beta of 0.84. Indivior has a one year low of $27.68 and a one year high of $42.81. The firm’s 50 day simple moving average is $35.20 and its 200 day simple moving average is $35.62.

Indivior (NASDAQ:INDV – Get Free Report) last issued its earnings results on Thursday, October 29th. The company reported $1.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.06 by $0.26. Indivior had a negative return on equity of 418.04% and a net margin of 32.75%. The company had revenue of $356.00 million for the quarter, compared to analysts’ expectations of $329.35 million. Equities research analysts expect that Indivior will post 3.66 EPS for the current year.

Insider Buying and Selling at Indivior

In other news, CAO Woodrow D. Anderson acquired 1,500 shares of the firm’s stock in a transaction on Thursday, August 27th. The stock was purchased at an average price of $35.69 per share, for a total transaction of $53,535.00. Following the purchase, the chief accounting officer owned 27,638 shares in the company, valued at approximately $986,400.22. This represents a 5.74% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.74% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Indivior in the 3rd quarter worth approximately $216,000. Profund Advisors LLC boosted its position in shares of Indivior by 268.8% in the 3rd quarter. Profund Advisors LLC now owns 49,650 shares of the company’s stock valued at $1,780,000 after purchasing an additional 36,188 shares during the period. Vise Technologies Inc. grew its stake in Indivior by 33.0% in the 3rd quarter. Vise Technologies Inc. now owns 9,298 shares of the company’s stock valued at $333,000 after buying an additional 2,306 shares during the last quarter. State of Wyoming raised its holdings in shares of Indivior by 75.5% in the third quarter. State of Wyoming now owns 6,505 shares of the company’s stock valued at $233,000 after buying an additional 2,799 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its position in shares of Indivior by 11.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 21,533 shares of the company’s stock valued at $788,000 after purchasing an additional 2,129 shares during the period. Institutional investors and hedge funds own 60.33% of the company’s stock.

About Indivior

(Get Free Report)

Indivior PLC (NASDAQ:INDV) is a global pharmaceutical company focused on developing and commercializing medicines for substance use disorders and serious mental health conditions. Its portfolio is centered on treatments for opioid use disorder, opioid overdose, and related medical needs.

The company’s principal products include Sublocade, an extended-release buprenorphine injection for opioid use disorder; Suboxone, a buprenorphine and naloxone treatment available in film and other formulations; and Opvee, a nalmefene nasal spray intended for the emergency treatment of known or suspected opioid overdose.

See Also